Richard C. Vaillant, MSA

An accomplished financial executive who has a successful track record for delivering impressive results. A financial executive Leading PE firm middle market Portfolio companies to Revenue, EBITDA Growth yielding high exit valuations / returns for shareholders. Provided a combined $1.1B in realized returns across three Portfolio companies.

Led Investment through Sales Process yielding returns from 5.9x to 7.4x return on invested capital. Led six (6) PE backed middle market Portfolio companies across Medical Device, Biologics and Physician Service sectors. Executed diligence, Tuck-in Acquisition, integration of 18 acquisitions across multiple life science companies.

Public Company Medical Device

Experience of a $430M Division in Vascular, Non-Vascular and Cardiology markets. Negotiated and Implemented Debt / Revolver facilities across multiple Portfolio companies. Lead Finance, HR, IT, S. Chain, Contracts teams supporting 100+% topline growth over hold periods across three companies (Medical Device and Biologics).

Recruited multiple Commercial teams (CDMO, Physician Services) supported by incentive-based Commission plans. Implementation of multiple business systems – ERP (QAD, SAP, Oracle), HRIS (ADP), QMS (Master control) at five portfolio companies providing business process efficiency and reduction in staffing requirements.

Chief Financial Officer Consultant - Axiom Real Time Metrics - Toronto, Canada

(2023-01 - 2025-12)

Axiom is a privately held PE backed (Great Point Partners) an Integrated eClinical Software Solution providing CRP services supporting Clinical Trials in all Therapeutic Indications.

• Led Restatement Financials for Fiscal years 2020- 2025
• Provided PE firm with Forensic accounting work to convert from Cash Hybrid to Accrual
• Revenue growth of $18m
• Led Restructuring of company in support of company exit June 2025

Chief Financial Officer - Bionova Scientific - Fremont, CA

(2020-01 - 2023-12)

Bionova is a privately held PE backed (Great Point Partners) global biologics Mammalian and Plasmid DNA CDMO providing cell-based solutions for all therapeutic indications.

• Grew Revenues from $2m to $46m over hold period
• Lead Deal Transaction in Sale of Company for $333m; 6.9x MOIC
• Manage Buildout of Facility expansion supporting Mammalian Mfg. Commercial & Clinical clean room, expansion of Quality Control and Process Development labs
• Hired and Managed - Finance, HR, IT, Program Management /Contracts and S. Chain
• Negotiated and implemented $25m debt / revolver facility
• Implemented integrated ERP (QAD) & QMS (Master-control) and Converted Financials from Cash to Accrual

Chief Financial Officer - Vitalink Research - Greenville SC

(2016-01 - 2020-12)

Vitalink is a privately held PE backed (Great Point Partners) Physician Services business supporting Pulmonary and Women's Health

• Lead Deal Transaction on Sale of company for PE firm
• Lead Tuck-in Acquisition Process (15 new clinics) and Integration post-acquisition
• Negotiated and Implemented Debt Facility
• Conversion from Cash to accrual account and Implementation of ERP (Clinical Conductor)

Chief Financial Officer - Cytovance Biologics, Inc. - Oklahoma City, OK

(2011-01 - 2016-12)

Cytovance is a privately held PE backed (Great Point Partners) global biologics Mammalian and Microbial CDMO providing cell-based solutions for all therapeutic indications.

• Grew Revenues from $6m to $55m over hold period
• Lead Deal Transaction in Sale of Company for $206m; 7.4x MOIC
• Hired and Managed - Finance, HR, IT, Contracts and Supply Chain
• Negotiated and implemented $20m debt / revolver facility
• Implemented ERP (QAD) and Converted Financials from Cash to Accrual

Chief Financial Officer - Histogenics Corporation - Waltham, MA

(2006-01 - 2011-12)

Histogenics is a privately held VC & Hedge fund backed early-stage Clinical Cartilage tissue biotechnology company

• Led company financials and Capitalization identification needs through successful Clinical Phase I and II trials
• Lead Deal Transaction in Sale of Company

Corporate Accounting Controller / Sr. Director FP&A – Corporate - American Cystoscope Makers Incorporated - Southborough, MA

(2000-01 - 2006-12)

ACMI is a privately held PE backed (Fox Paine Investments), $240M medical device manufacturing company, focused on delivering innovative Cystoscopes for Urology, Endoscopy and Gynecology Markets

• Managed all Accounting, Financial Statement and Analytics, Revenue grew from $110m to $240m over hold period while driving 23% EBITDA through Revenue growth and business restructuring
• Managed Sale process (with CFO) of Company to Gyrus Medical for $526m a 5.9x MOIC
• Partnered with Management team and BOD to re-engineer and implement process and systems improvements (Oracle)
• Finance business partner to COO in restructuring company business units, functional departments and facilities to align with refocused market strategy
• Standardized all accounting to be GAAP compliant

Division Controller- Meadox ($150m Revenue, Surgical Graft) - Boston Scientific Corporation (NYSE – BSX) - Natick, MA

(1988-01 - 2000-12)

BSC is a publicly traded medical device manufacturer for all therapeutic indications

SAP ERP Implementation Leader (Global Implementation, 12 Divisions) - Boston Scientific Corporation (NYSE – BSX) - Natick, MA

(1996-01 - 1998-12)

BSC is a publicly traded medical device manufacturer for all therapeutic indications

Division Controller – Meditech ($430m Revenue, Catheters, Guidewires, Filters) - Boston Scientific Corporation (NYSE – BSX) - Natick, MA

(1991-01 - 1996-12)

BSC is a publicly traded medical device manufacturer for all therapeutic indications

Cost Accounting Manager - Boston Scientific Corporation (NYSE – BSX) - Natick, MA

(1988-01 - 1991-12)

BSC is a publicly traded medical device manufacturer for all therapeutic indications

M.S.A - Accounting - Suffolk University (2008-01 - 2009-12)

B.S. - Accounting - Merrimack College (1979-01 - 1984-12)